Cargando…
PNPLA 3 I148M genetic variant associates with insulin resistance and baseline viral load in HCV genotype 2 but not in genotype 3 infection
BACKGROUND: Hepatic steatosis in HCV patients has been postulated as a risk factor associated with a higher frequency of fibrosis and cirrhosis. A single genetic variant, PNPLA3 I148M, has been widely associated with increased hepatic steatosis. Previous studies of the PNPLA3 I148M sequence variant...
Autores principales: | Rembeck, Karolina, Maglio, Cristina, Lagging, Martin, Christensen, Peer Brehm, Färkkilä, Martti, Langeland, Nina, Buhl, Mads Rauning, Pedersen, Court, Mørch, Kristine, Norkrans, Gunnar, Hellstrand, Kristoffer, Lindh, Magnus, Pirazzi, Carlo, Burza, Maria Antonella, Romeo, Stefano, Westin, Johan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495049/ https://www.ncbi.nlm.nih.gov/pubmed/22978414 http://dx.doi.org/10.1186/1471-2350-13-82 |
Ejemplares similares
-
Impact of IL28B-Related Single Nucleotide Polymorphisms on Liver Histopathology in Chronic Hepatitis C Genotype 2 and 3
por: Rembeck, Karolina, et al.
Publicado: (2012) -
Impact of Obesity on the Bioavailability of Peginterferon-α2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3
por: Alsiö, Åsa, et al.
Publicado: (2012) -
A Novel Fibrosis Index Comprising a Non-Cholesterol Sterol Accurately Predicts HCV-Related Liver Cirrhosis
por: Ydreborg, Magdalena, et al.
Publicado: (2014) -
Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience
por: Waldenström, Jesper, et al.
Publicado: (2016) -
Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection
por: Waldenström, Jesper, et al.
Publicado: (2016)